Kenacort-A 40

Triamcinolone Acetonide, the active ingredient in Kenacort-A 40, is a corticosteroid (glucocorticoid) presented as a sterile injectable preparation for intra‑articular, intrabursal and intramuscular use. It is employed to reduce inflammation and pain in various joint and soft‑tissue conditions, particularly in adult patients with inflammatory musculoskeletal disorders.

GNH USA supplies Kenacort-A 40 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kenacort-A 40 is a glucocorticoid used to manage inflammatory conditions of the musculoskeletal system by direct injection into the affected site.

Rheumatoid arthritis: diminishes synovial inflammation and joint pain when injected intra‑articularly. Osteoarthritis: alleviates joint swelling and improves mobility in affected joints. Bursitis: reduces bursal inflammation and discomfort after intrabursal administration. Tendinitis: suppresses tendon sheath inflammation and pain when given intratendinously. Inflammatory joint conditions requiring intra‑articular injection: provides rapid anti‑inflammatory effect to improve function.

Kenacort‑A 40 may cause a range of adverse reactions following injection.

Common Side Effects: - Local pain or tenderness at the injection site. - Transient swelling or erythema. - Mild increase in blood glucose in diabetic patients. - Temporary bruising or discoloration. - Minor headache.

Serious or Rare Side Effects: - Joint infection (septic arthritis). - Tendon rupture or weakening. - Osteonecrosis of the bone. - Systemic adrenal suppression with repeated dosing. - Allergic reaction including urticaria or anaphylaxis.

Before using Kenacort‑A 40, consider the following safety measures.

Avoid use in patients with active infection at the injection site: risk of spreading infection. Monitor blood glucose in diabetic patients: glucocorticoids can raise glucose levels. Limit frequency of injections: repeated use may cause tissue atrophy or systemic effects. Screen for hypersensitivity to corticosteroids: prior allergic reactions increase risk. Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Kenacort‑A 40 can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Systemic corticosteroids: additive immunosuppression and adrenal suppression. - Anticoagulants (e.g., warfarin): increased risk of bleeding at injection site. - Live vaccines: reduced vaccine efficacy and possible infection.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase local irritation. - Diuretics: potential for electrolyte imbalance. - Antidiabetic agents: may require dose adjustment due to hyperglycaemia.